[go: up one dir, main page]

BRPI0510221A - composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição - Google Patents

composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição

Info

Publication number
BRPI0510221A
BRPI0510221A BRPI0510221-9A BRPI0510221A BRPI0510221A BR PI0510221 A BRPI0510221 A BR PI0510221A BR PI0510221 A BRPI0510221 A BR PI0510221A BR PI0510221 A BRPI0510221 A BR PI0510221A
Authority
BR
Brazil
Prior art keywords
composition
aryl ketone
preparing
ketone compound
dosage form
Prior art date
Application number
BRPI0510221-9A
Other languages
English (en)
Inventor
Parshuram Rath
Maria Isabel Gomez-Orellana
Edmund A Vuocolo
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0510221A publication Critical patent/BRPI0510221A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTO DE ARIL CETONA, COMPOSIçãO, FORMA DE DOSAGEM UNITáRIA, USO DA COMPOSIçãO E MéTODO PARA PREPARAR UMA COMPOSIçãO. A presente invenção provê compostos de aril cetona e compostos contendo-os, que facilitam a liberação de agentes ativos. Os compostos de aril cetona têm a fórmula (1) ou um sal destes onde n é um número inteiro de 1 a 9, e R¬ 1¬ a R¬ 5¬ são independentemente hidrogênio, alquila C~ 1~ a C~ 6~, alcóxi C~ 1~ a C~ 6~, alquenila C~ 2~ a C~ 6~, halogênio, hidroxila, NH-C(O)-CH~ 3~, ou -O-C~ 6~H~ 5~.
BRPI0510221-9A 2004-05-14 2005-05-16 composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição BRPI0510221A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57109004P 2004-05-14 2004-05-14
US57109204P 2004-05-14 2004-05-14
PCT/US2005/017339 WO2005117854A2 (en) 2004-05-14 2005-05-16 Aryl ketone compounds and compositions for delivering active agents

Publications (1)

Publication Number Publication Date
BRPI0510221A true BRPI0510221A (pt) 2007-10-23

Family

ID=35463319

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510221-9A BRPI0510221A (pt) 2004-05-14 2005-05-16 composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição

Country Status (10)

Country Link
US (1) US9035085B2 (pt)
EP (1) EP1745004B8 (pt)
JP (1) JP4995080B2 (pt)
AU (1) AU2005249410A1 (pt)
BR (1) BRPI0510221A (pt)
CA (1) CA2566161C (pt)
ES (1) ES2586423T3 (pt)
MX (1) MXPA06013251A (pt)
NZ (1) NZ551241A (pt)
WO (1) WO2005117854A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510221A (pt) * 2004-05-14 2007-10-23 Emisphere Tech Inc composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição
WO2007005995A2 (en) 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
CN104884065B (zh) 2012-09-21 2019-01-01 强烈治疗剂公司 治疗癌症的方法
DK3104853T3 (da) 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2020006224A1 (en) 2018-06-27 2020-01-02 Cornell University Substituted alkylphenols as hcn1 antagonists
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447998A (en) * 1945-09-18 1948-08-24 American Cyanamid Co Preparation of substituted acylanilides
US3046301A (en) * 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
US3720690A (en) * 1970-04-10 1973-03-13 Fisons Pharmaceuticals Ltd Pharmaceutically active bis-carboxychromone compounds
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US4407757A (en) * 1974-05-02 1983-10-04 Takeda Chemical Industries, Ltd. Aralkyl carboxylic acid compounds
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4544565A (en) * 1984-03-29 1985-10-01 General Foods Corporation Foodstuffs containing sweetness inhibiting agents
EP0191724A3 (de) * 1985-01-15 1986-12-03 Sandoz Ag 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
AU675778B2 (en) 1991-11-27 1997-02-20 Bioresearch Inc. Specific eatable taste modifiers
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
EP1077070A3 (en) 1993-04-22 2001-05-23 Emisphere Technologies, Inc. Oral drug delivery compositions
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU5732296A (en) * 1995-05-08 1996-11-29 Texas Biotechnology Corporation Method for inhibiting the binding of selectins to sialyl-lew ises
IL118657A0 (en) * 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4675481B2 (ja) 1998-07-27 2011-04-20 エミスフェアー・テクノロジーズ・インク 活性剤の肺性デリバリー
CZ302280B6 (cs) 1998-08-07 2011-01-26 Emisphere Technologies, Inc. Slouceniny a prostredky pro dodávání aktivních látek
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
WO2000047188A1 (en) 1999-02-11 2000-08-17 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
ATE288415T1 (de) 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
DE60041976D1 (de) 1999-11-05 2009-05-20 Emisphere Tech Inc Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
AU2274201A (en) 1999-12-16 2001-06-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
DK1299348T3 (da) 2000-06-29 2008-07-28 Emisphere Tech Inc Forbindelser og sammensætninger til levering af aktive midler
US7138546B2 (en) 2000-08-18 2006-11-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1326825A2 (en) 2000-08-18 2003-07-16 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PT1317419E (pt) 2000-09-06 2009-05-08 Emisphere Tech Inc Compostos e composições de ácido cianofenoxicarboxílico para administrar agentes activos
DE60134245D1 (de) 2000-09-06 2008-07-10 Emisphere Tech Inc (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
FR2817256B1 (fr) * 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
CR6574A (es) * 2001-02-27 2004-10-28 Syngenta Participations Ag Sales de avermectinas substituidas en la posicion 4 con propiedades plaguicidas
JP2004530658A (ja) 2001-03-01 2004-10-07 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US7615233B2 (en) * 2001-07-10 2009-11-10 Canon Kabushiki Kaisha Particulate construct comprising polyhydroxyalkanoate and method for producing it
JP4602668B2 (ja) 2001-11-13 2010-12-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するためのフェノキシアミン化合物および組成物
JP2006507303A (ja) * 2002-11-01 2006-03-02 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
BRPI0510221A (pt) * 2004-05-14 2007-10-23 Emisphere Tech Inc composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição

Also Published As

Publication number Publication date
US9035085B2 (en) 2015-05-19
AU2005249410A1 (en) 2005-12-15
EP1745004B8 (en) 2016-07-27
WO2005117854A2 (en) 2005-12-15
CA2566161C (en) 2013-10-01
EP1745004A4 (en) 2007-05-09
MXPA06013251A (es) 2007-02-28
WO2005117854A3 (en) 2006-10-12
US20080167217A1 (en) 2008-07-10
ES2586423T3 (es) 2016-10-14
NZ551241A (en) 2010-08-27
EP1745004B1 (en) 2016-05-18
CA2566161A1 (en) 2005-12-15
JP2007538014A (ja) 2007-12-27
JP4995080B2 (ja) 2012-08-08
EP1745004A2 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
ECSP066667A (es) Derivados de ciclohexano espirociclicos
NO20055590L (no) Kinaseinhiberende fosfonatanaloger
BRPI0510221A (pt) composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição
EA200970156A1 (ru) Пиридизиноновые производные
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
CY1112201T1 (el) Φαρμακο για τη θεραπευτικη αγωγη γριπης
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ATE433447T1 (de) Pyrimiidinverbindungen
BR0010520A (pt) Novos compostos farmaceuticamente ativos
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
UY28745A1 (es) Nuevos compuestos
BRPI0617654B8 (pt) composto, composição farmacêutica e processo para preparar o composto
TW200724166A (en) Wrinkle-improving agent
NO20074002L (no) Androgen reseptor-modulatorforbindelser og fremgangsmater
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112012013511A2 (pt) derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
BRPI0515628A (pt) composto de 2-morfolina-4-pirimidona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]